We are delighted to invite you to read the latest 20 Years of SMA Europe: From firefighting to future-building by Rare Revolution Magazine.
We are pleased to share a community letter from Roche, announcing that the EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update to the European label for the risdiplam tablet.
We regret to inform that Roche has decided not to advance emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for SMA, leading to the discontinuation of the MANATEE clinical study.